Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of background therapy with atenolol in patients with stable angina pectoris. A four-month randomised double-blind, parallel group international multicentre study

Trial Profile

Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of background therapy with atenolol in patients with stable angina pectoris. A four-month randomised double-blind, parallel group international multicentre study

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Angina pectoris; Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms ASSOCIATE
  • Most Recent Events

    • 15 Jun 2011 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
    • 30 Aug 2008 Endpoint 'Time to exercise induced ECG change' has been met (results reported at ESC 2008).
    • 30 Aug 2008 Endpoint 'Time to exercise induced angina pectoris' has been met (results reported at ESC 2008).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top